What is FlexDex?
FlexDex specializes in the development of advanced surgical instruments designed to provide surgeons with the dexterity and precision of robotic systems without the prohibitive costs associated with large-scale robotic platforms. By leveraging a unique, mechanical approach to minimally invasive surgery, the company enables clinicians to perform complex procedures with enhanced control and ergonomic efficiency. Based in Brighton, Michigan, FlexDex occupies a critical niche in the medical technology market, focusing on democratizing access to high-performance surgical tools that improve patient outcomes while maintaining operational efficiency for healthcare providers.
How much funding has FlexDex raised?
FlexDex has raised a total of $23.8M across 6 funding rounds:
Series A
$825K
Series B
$5M
Debt
$4.3M
Debt
$350K
Debt
$368K
Other Financing Round
$13M
Series A (2014): $825K, investors not publicly disclosed
Series B (2016): $5M, investors not publicly disclosed
Debt (2017): $4.3M, investors not publicly disclosed
Debt (2020): $350K featuring PPP
Debt (2021): $368K backed by PPP
Other Financing Round (2021): $13M with participation from Almeda Ventures and Johnson & Johnson Innovation
Key Investors in FlexDex
Johnson & Johnson Innovation
Johnson & Johnson Innovation is a global leader in healthcare, partnering with early-stage businesses to develop transformational medical solutions through a network of regional innovation centers.
Almeda Ventures
Almeda Ventures is a specialized investment firm focused on identifying and supporting high-growth companies within the healthcare and life sciences sectors.
PPP
Public-Private Partnership
What's next for FlexDex?
With the recent influx of capital, FlexDex is expected to prioritize the expansion of its manufacturing capabilities and the broader adoption of its platform across clinical settings. The strategic involvement of industry-leading partners suggests a focus on scaling the commercial distribution of its instruments and potentially integrating its technology into broader healthcare ecosystems. As the company moves into this next phase of development, the focus will likely shift toward clinical validation, regulatory milestones, and the continued refinement of its product pipeline to address the evolving needs of the global surgical community.
See full FlexDex company page
